RLAY

Rating neutralAI MemoPost-earnings T+3

Relay Therapeutics

As of 2026-05-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Initial vascular anomalies data remain the nearest clean clinical readout • 2026-05-20

Expected move: -28%

Biggest risk

The bear case is that little in the Q1 print fundamentally de-risked the core binary questions. Revenue remains immaterial, losses continue, and the thesis still depends on future clinical readouts and regulatory execution rather than a broadened evidence base. Trustworthy post-print analyst revision evidence was not clearly available in checked sources, so the positive read-through is incomplete.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

The post-earnings bull case is that May 5 preserved the constructive 2026 setup: cash runway now reaches into 2029, the May vascular-anomalies readout is near, ReDiscover-2 remains active, and management advanced the frontline triplet plan toward an early-2027 Phase 3 start.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$14

p=50%

Bull target

$17

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 update extended cash runway and kept the zovegalisib calendar active
Breast-cancer program execution still hinges on Phase 3 and frontline triplet follow-through
The post-earnings bull case is that May 5 preserved the constructive 2026 setup: cash runway now reaches into 2029, the May vascular-anomalies readout is near, ReDiscover-2 remains active, and management advanced the frontline triplet plan toward an early-2027 Phase 3 start.

BearKey bullets

Checked sources did not surface a clear wave of post-earnings analyst target revisions, leaving external validation of the May 5 update limited.
Clinical-stage concentration remains high, with zovegalisib still carrying most of the equity story.
Despite improved runway, Relay remains loss-making and has no commercial revenue base to absorb clinical delays.

WatchKey bullets

Initial vascular anomalies data remain the nearest clean clinical readout

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $14 (p=50%)

Bull/Bear spread: -9% / -54%

Vs latest close: Bull -9% · Base -28% · Bear -54%

Scenario probabilities

Bull Target: $17 (p=25%)Base Target: $14 (p=50%)Bear Target: $9 (p=25%)

Commentary

This is still a monitoring-style T+3 earnings memo, not a conviction upgrade. Primary-source support is solid after the May 5 8-K, 10-Q, and company earnings release, but external revision evidence remains thin. The stock’s anchor moved from $13.03 on 2026-04-28 in the prior baseline to $12.51 on 2026-05-07, which suggests mildly negative post-print digestion even though cash runway improved and milestones stayed on track. With no trustworthy checked evidence of a meaningful post-earnings analyst rerating, the tone stays cautious rather than decisively bullish.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 update extended cash runway and kept the zovegalisib calendar active
Breast-cancer program execution still hinges on Phase 3 and frontline triplet follow-through

Scenarios

Bull Target (Scenario probability)

$17 / p=25% prob

Base Target (Scenario probability)

$14 / p=50% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Price $19 as of 2026-07-27

Nearest Scenario: Bull (∆ 9%)

Targets vs latest close: Bull -9% · Base -28% · Bear -54%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-20
Initial vascular anomalies data remain the nearest clean clinical readout
Relay previously guided to initial zovegalisib clinical results in PIK3CA-driven vascular anomalies at ISSVA World Congress 2026 on May 20, 2026, and the May 5 Q1 update again flagged a May 19 conference call during ISSVA. This is the next discrete proof-of-concept checkpoint beyond breast-cancer narrative updates [#PR-2026-04-02] [#PR-2026-05-05].
Prob 70.00% • Move 14.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Q1 update extended cash runway and kept the zovegalisib calendar active
2026-05-19
Relay’s May 5 earnings release said cash, cash equivalents and investments ended Q1 2026 at approximately $642 million and should fund operations into 2029, while also reiterating a May 19 vascular-anomalies data event and ongoing breast-cancer execution. That reduces near-term financing pressure but does not remove clinical-event dependence [#8-K-2026-05-05] [#PR-2026-05-05].
Prob 80% • Move 8% • Priced-in 60%

Long-term Catalysts

Months to a year

Breast-cancer program execution still hinges on Phase 3 and frontline triplet follow-through
2027-03-31
Relay’s core value driver remains zovegalisib. The company said ReDiscover-2 is ongoing, FDA Breakthrough Therapy designation was granted in February 2026 for the fulvestrant doublet setting, and the zovegalisib plus atirmociclib triplet is the go-forward frontline regimen with a Phase 3 study expected to start in early 2027, subject to regulatory feedback. That is strategically positive, but the setup is still clinical-execution heavy rather than commercially de-risked [#10-Q-2026-05-05] [#PR-2026-05-05] [#8-K-2026-04-27].
Prob 60% • Move 20% • Priced-in 55%

Risks

Checked sources did not surface a clear wave of post-earnings analyst target revisions, leaving external validation of the May 5 update limited.
Clinical-stage concentration remains high, with zovegalisib still carrying most of the equity story.
Despite improved runway, Relay remains loss-making and has no commercial revenue base to absorb clinical delays.
Management’s planned frontline Phase 3 triplet start in early 2027 is still subject to regulatory feedback and execution risk.
Near-term sentiment can turn quickly if ISSVA vascular-anomalies data are mixed or fail to broaden confidence beyond breast cancer.

Peers

Symbol	Summary
IDYA	IDEAYA is a closer small-cap precision-oncology development peer by stage and valuation, though its pipeline differs; peer sentiment helps frame how much RLAY still trades on milestone timing versus marketed-product economics.
ELVN	Enliven is another similarly sized clinical oncology peer where valuation is driven by program readouts and regulatory path, making it a reasonable comparison for binary catalyst risk rather than indication overlap.
MLYS	Mineralys is less mechanistically similar but is a useful small-cap biotech valuation peer for cash-runway, single-asset concentration, and event-risk discounting.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-08

AI Stock Memo: RLAY - Relay Therapeutics - RankAlpha